-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $650

Benzinga·11/03/2026 15:21:33
Listen to the news
Wells Fargo analyst Mohit Bansal maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $550 to $650.